241 related articles for article (PubMed ID: 10090944)
21. Cord blood comprises antigen-experienced T cells specific for maternal minor histocompatibility antigen HA-1.
Mommaas B; Stegehuis-Kamp JA; van Halteren AG; Kester M; Enczmann J; Wernet P; Kögler G; Mutis T; Brand A; Goulmy E
Blood; 2005 Feb; 105(4):1823-7. PubMed ID: 15498856
[TBL] [Abstract][Full Text] [Related]
22. Redirection of antileukemic reactivity of peripheral T lymphocytes using gene transfer of minor histocompatibility antigen HA-2-specific T-cell receptor complexes expressing a conserved alpha joining region.
Heemskerk MH; Hoogeboom M; de Paus RA; Kester MG; van der Hoorn MA; Goulmy E; Willemze R; Falkenburg JH
Blood; 2003 Nov; 102(10):3530-40. PubMed ID: 12869497
[TBL] [Abstract][Full Text] [Related]
23. Quantification of the HA-1 gene product at the RNA level; relevance for immunotherapy of hematological malignancies.
Wilke M; Dolstra H; Maas F; Pool J; Brouwer R; Falkenburg JH; Rebello A; Lamers F; Schuuring E; Kluin P; Brasseur F; Goulmy E
Hematol J; 2003; 4(5):315-20. PubMed ID: 14502255
[TBL] [Abstract][Full Text] [Related]
24. Minor histocompatibility antigen-specific, leukemia-reactive cytotoxic T cell clones can be generated in vitro without in vivo priming using chronic myeloid leukemia cells as stimulators in the presence of alpha-interferon.
Faber LM; van Luxemburg-Heijs SA; Rijnbeek M; Willemze R; Falkenburg JH
Biol Blood Marrow Transplant; 1996 Feb; 2(1):31-6. PubMed ID: 9078352
[TBL] [Abstract][Full Text] [Related]
25. Allorestricted cytotoxic T cells specific for human CD45 show potent antileukemic activity.
Amrolia PJ; Reid SD; Gao L; Schultheis B; Dotti G; Brenner MK; Melo JV; Goldman JM; Stauss HJ
Blood; 2003 Feb; 101(3):1007-14. PubMed ID: 12393606
[TBL] [Abstract][Full Text] [Related]
26. Targeting a single mismatched minor histocompatibility antigen with tumor-restricted expression eradicates human solid tumors.
Hambach L; Vermeij M; Buser A; Aghai Z; van der Kwast T; Goulmy E
Blood; 2008 Sep; 112(5):1844-52. PubMed ID: 18544677
[TBL] [Abstract][Full Text] [Related]
27. Induction of minor histocompatiblity antigen HA-1-specific cytotoxic T cells for the treatment of leukemia after allogeneic stem cell transplantation.
Brossart P; Spahlinger B; Grünebach F; Stuhler G; Reichardt VL; Kanz L; Brugger
Blood; 1999 Dec; 94(12):4374-6. PubMed ID: 10636695
[No Abstract] [Full Text] [Related]
28. Up-regulated expression in nonhematopoietic tissues of the BCL2A1-derived minor histocompatibility antigens in response to inflammatory cytokines: relevance for allogeneic immunotherapy of leukemia.
Kloosterboer FM; van Luxemburg-Heijs SA; van Soest RA; van Egmond HM; Willemze R; Falkenburg JH
Blood; 2005 Dec; 106(12):3955-7. PubMed ID: 16099884
[TBL] [Abstract][Full Text] [Related]
29. [Construction of HA-1-DC nucleic-acid vaccine and induction of specific cytotoxic T lymphocytes].
Wang YY; Zhang DH; Liu WL; Zhou HS; Zhang L; Dai M; Huang ZQ; Tan H; Xiong P
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2006 Dec; 14(6):1178-82. PubMed ID: 17204189
[TBL] [Abstract][Full Text] [Related]
30. Construction of HA-1-DC nucleic-acid vaccine and induction of specific cytotoxic T lymphocytes.
Wang Y; Zhang D; Hu J; Liu W; Zhou H; Zhang L; Liu D; Huang Z; Tan H
J Huazhong Univ Sci Technolog Med Sci; 2007 Jun; 27(3):261-4. PubMed ID: 17641837
[TBL] [Abstract][Full Text] [Related]
31. Peptide length extension skews the minor HA-1 antigen presentation toward activated dendritic cells but reduces its presentation efficiency.
Hambach L; Aghai Z; Pool J; Kröger N; Goulmy E
J Immunol; 2010 Oct; 185(8):4582-9. PubMed ID: 20855877
[TBL] [Abstract][Full Text] [Related]
32. Presentation of tumor antigens by phagocytic dendritic cell clusters generated from human CD34+ hematopoietic progenitor cells: induction of autologous cytotoxic T lymphocytes against leukemic cells in acute myelogenous leukemia patients.
Fujii S; Fujimoto K; Shimizu K; Ezaki T; Kawano F; Takatsuki K; Kawakita M; Matsuno K
Cancer Res; 1999 May; 59(9):2150-8. PubMed ID: 10232602
[TBL] [Abstract][Full Text] [Related]
33. Generation of donor-derived Wilms tumor antigen 1-specific cytotoxic T lymphocytes with potent anti-leukemia activity for somatic cell therapy in children given haploidentical stem cell transplantation: a feasibility pre-clinical study.
Ferulli F; Tanzi M; Turin I; Montini E; Rosti V; Acquafredda G; Lisini D; Compagno F; Boghen S; Licari A; Marseglia G; Zecca M; Montagna D
Cytotherapy; 2019 Sep; 21(9):958-972. PubMed ID: 31279696
[TBL] [Abstract][Full Text] [Related]
34. The hematopoietic system-specific minor histocompatibility antigen HA-1 shows aberrant expression in epithelial cancer cells.
Klein CA; Wilke M; Pool J; Vermeulen C; Blokland E; Burghart E; Krostina S; Wendler N; Passlick B; Riethmüeller G; Goulmy E
J Exp Med; 2002 Aug; 196(3):359-68. PubMed ID: 12163564
[TBL] [Abstract][Full Text] [Related]
35. Growth inhibition of clonogenic leukemic precursor cells by minor histocompatibility antigen-specific cytotoxic T lymphocytes.
Falkenburg JH; Goselink HM; van der Harst D; van Luxemburg-Heijs SA; Kooy-Winkelaar YM; Faber LM; de Kroon J; Brand A; Fibbe WE; Willemze R
J Exp Med; 1991 Jul; 174(1):27-33. PubMed ID: 2056279
[TBL] [Abstract][Full Text] [Related]
36. The in vitro generation of multi-tumor antigen-specific cytotoxic T cell clones: Candidates for leukemia adoptive immunotherapy following allogeneic stem cell transplantation.
Mohamed YS; Bashawri LA; Vatte C; Abu-Rish EY; Cyrus C; Khalaf WS; Browning MJ
Mol Immunol; 2016 Sep; 77():79-88. PubMed ID: 27490939
[TBL] [Abstract][Full Text] [Related]
37. Generation of melanoma-specific cytotoxic T lymphocytes for allogeneic immunotherapy.
Nolte A; Scheffold C; Slotty J; Huenefeld C; Schultze JL; Grabbe S; Berdel WE; Kienast J
J Immunother; 2003; 26(3):257-69. PubMed ID: 12806279
[TBL] [Abstract][Full Text] [Related]
38. Exogenous Addition of Minor H Antigen HA-1+ Dendritic Cells to Skin Tissues Ex Vivo Causes Infiltration and Activation of HA-1-Specific Cytotoxic T Cells.
Kim YH; Vyth-Dreese FA; Schrama E; Pavel S; Bajema I; Goulmy E; Spierings E
Biol Blood Marrow Transplant; 2011 Jan; 17(1):69-77. PubMed ID: 20708701
[TBL] [Abstract][Full Text] [Related]
39. Towards effective and safe immunotherapy after allogeneic stem cell transplantation: identification of hematopoietic-specific minor histocompatibility antigen UTA2-1.
Oostvogels R; Minnema MC; van Elk M; Spaapen RM; te Raa GD; Giovannone B; Buijs A; van Baarle D; Kater AP; Griffioen M; Spierings E; Lokhorst HM; Mutis T
Leukemia; 2013 Mar; 27(3):642-9. PubMed ID: 23079962
[TBL] [Abstract][Full Text] [Related]
40. Identification of 4 new HLA-DR-restricted minor histocompatibility antigens as hematopoietic targets in antitumor immunity.
Stumpf AN; van der Meijden ED; van Bergen CA; Willemze R; Falkenburg JH; Griffioen M
Blood; 2009 Oct; 114(17):3684-92. PubMed ID: 19706888
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
